GPCM
ADMS

Granite Point Capital Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Granite Point Capital Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-46,000
Closed -$174K – 116
2019
Q4 		$174K Buy
+46,000
New +$220K 0.03% 85

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Granite Point Capital Management's ADMS Position: Q3 2019 in Review

Granite Point Capital Management sold out of Adamas Pharmaceuticals (ADMS) in Q3 2019, closing a stake of 54,822 shares — an estimated $340K sold.

Granite Point Capital Management first reported a position in ADMS in Q3 2014 and held it in 19 quarters. The position peaked at $9.17M in Q4 2017. 87 funds tracked by Wall St. Rank hold ADMS as of Q3 2019.

  • Granite Point Capital Management reported no remaining Adamas Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Granite Point Capital Management sold 54,822 Adamas Pharmaceuticals shares in Q3 2019, an estimated $340K.
  • Granite Point Capital Management first reported a position in Adamas Pharmaceuticals in Q3 2014 and held it in 19 quarters.
  • Granite Point Capital Management's Adamas Pharmaceuticals position peaked at $9.17M in Q4 2017.
  • 87 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2019.

Based on Granite Point Capital Management's 13F filing for Q3 2019, filed 30 Oct 2019.